Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Recombinant Human Interleukin-15 Clear all
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 18, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)

NCT01385423
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Preparative Regimen, Intravenous Recombinant Human IL-15 (rhIL-15)
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 18, 2026, 11:22 AM EDT
Withdrawn Phase 2 Interventional

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

NCT03574649
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 18, 2026, 11:22 AM EDT
Withdrawn Phase 2 Interventional

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

NCT03554109
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 18, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

NCT02395822
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
IL-15
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 18, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

NCT01875601
View directory record Official record
Conditions
Solid Tumors, Brain Tumors, Sarcoma, Pediatric Cancers, Neuroblastoma
Interventions
Recombinant human interleukin-15 (rhIL-15), NK Cell Infusion
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 29 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 18, 2026, 11:22 AM EDT
Recruiting Phase 1 Interventional

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

NCT05618925
View directory record Official record
Conditions
Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions
N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newport Beach, California • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03329248
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

NCT03563157
View directory record Official record
Conditions
Colorectal Cancer Metastatic, mCRC
Interventions
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Recruiting Phase 2 Interventional

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

NCT06239220
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
PD-L1 t-haNK, Cetuximab, NAI
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1 Interventional Results available

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

NCT04385849
View directory record Official record
Conditions
COVID-19
Interventions
N-803, Saline
Biological · Other
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Results available

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

NCT03905135
View directory record Official record
Conditions
Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma
Interventions
rhIL-15, Avelumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 18, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT04390399
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 18, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Results available

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

NCT04185220
View directory record Official record
Conditions
Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides
Interventions
Recombinant human Interleukin-15 (rhIL-15), Mogamulizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 18, 2026, 11:22 AM EDT
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

NCT03647423
View directory record Official record
Conditions
Chordoma, Unresectable Malignant Neoplasm
Interventions
Aldoxorubicin Hydrochloride, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, Avelumab, Cetuximab, Cyclophosphamide, SBRT
Biological · Drug · Radiation
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 18, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Results available

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

NCT01572493
View directory record Official record
Conditions
Lymphoma, Carcinoma
Interventions
rh IL-15 (10 DAYS), rh IL-15 (5 DAYS)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03387098
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.080: NANT Pancreatic Cancer Vaccine

NCT03586869
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Oxaliplatin, Avelumab, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

NCT03387111
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, SBRT, N-803
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

NCT02465957
View directory record Official record
Conditions
Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Interventions
aNK (NK-92), aNK (NK-92) + N-803
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

NCT03853317
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Avelumab, N-803, haNK™
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03136406
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, Oxaliplatin, Capecitabine, 5-Fluorouracil, Leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK for Infusion, ETBX-011, GI-4000
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 18, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

NCT01727076
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 18, 2026, 11:22 AM EDT